The Cost Consequences of Treatment-Resistant Depression
The DOI matches its Crossref record.
Abstract
CONTEXT: Treatment-resistant depression is a significant public health problem with profound effects on general medical and mental health-related health care costs. OBJECTIVE: To describe health care costs of patients with treatment-resistant depression as their illness progresses, in terms of pharmaceutical and medical expenditures, and to identify factors associated with increasing degrees of treatment resistance. DATA SOURCES: The MEDSTAT MarketScan Private Pay Fee for Service (FFS) Database, a medical and prescription claims database covering over 3.5 million enrollees, from 1995-2000. DESIGN AND STUDY SUBJECTS: 7737 patients with depression (ICD-9) who had 2 or more unsuccessful trials of antidepressant medication at an adequate dose for at least 4 weeks from 1995-2000 were defined as treatment-resistant in this study. Demographic and clinical characteristics were assessed for these patients with treatment-resistant depression. The number of changes in depression medication treatment regimens was used as a proxy for increasing degrees of treatment resistance and its severity. MAJOR OUTCOME MEASURE: Differences in health care expenditures associated with increasing degrees of treatment-resistant depression. RESULTS: Total depression-related and general medical health care expenditures increased significantly as treatment-resistant depression increased in severity. Multivariate analyses of patient demographic characteristics were not associated with ongoing treatment resistance. Disease severity, type of antidepressant at index, comorbid mental health disorders, and membership in a managed health care plan were associated with increasing degrees of treatment resistance. CONCLUSIONS: Depression and general medical health care expenditures increase with the degree of treatment-resistant depression. Disease management interventions for treatment-resistant depression that result in sustained remission early in the course of illness are most likely to be cost effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prevalence and clinical course of depression: a review
Richards, D. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.07.004 · Cited by 623
(2007) · PubMed · Cited by 453
Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010) · Depression and Anxiety · doi:10.1002/da.20580 · Cited by 380
Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., Jonas, D. E., Evans, T. S., Viswanathan, M., & Lohr, K. N. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08815 · Cited by 347
Donohue, J. M., & Pincus, H. A. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725010-00003 · Cited by 214
Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C., McInnes, L. A., Mathalon, D. H., & Feldman, M. D. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442260 · Cited by 187
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
(2010) · PubMed · Cited by 157
Acetyl- l -carnitine deficiency in patients with major depressive disorder
Nasca, C., Bigio, B., Lee, F. S., Young, S. P., Kautz, M. M., Albright, A., Beasley, J., Millington, D. S., Mathé, A. A., Kocsis, J. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801609115 · Cited by 152
“A subgroup of 18 patients with MDD recruited at Icahn School of Medicine at Mount Sinai reported history of TRD defined by at least two failed antidepressant trials (41, 42).”
BackgroundThe Economic Burden of Treatment-Resistant Depression
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.001 · Cited by 146
Defining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130
“22 Regarding utilization of services, TRD patients were twice as likely to be hospitalized and had 12% more outpatient visits compared with non-TRD patients.”
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
“Their courses of depression are marked by chronicity, polypharmacy, poor functioning and quality of life, a high level of suicidality both through ideation and behavior, and a high level of psychiatric and medical co-morbidity with high utilization of services (Kubitz et al., 2013; Rush et al., 2006b, 2012; Russell et…”
BackgroundSelf-citationSackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
Self-citationTranscranial magnetic stimulation (TMS) for geriatric depression
Cappon, D., den Boer, T., Jordan, C., Yu, W., Metzger, E., & Pascual-Leone, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101531 · Cited by 97
Finding factors that predict treatment-resistant depression: results of a cohort study
Cepeda, M. S., Reps, J., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22774 · Cited by 80
Clarke, S., Kingston, J., James, K., Bolderston, H., & Remington, B. (2014) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2014.04.005 · Cited by 79
Peeters, F. P. M. L., Ruhe, H. G., Wichers, M., Abidi, L., Kaub, K., van der Lande, H. J., Spijker, J., Huibers, M. J. H., & Schene, A. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.08.019 · Cited by 72
“TRD is associated with high personal suffering, considerable functional impairment, and significant medical and mental health costs (Gibson et al., 2010; Petersen et al., 2004; Russell et al., 2004).”
BackgroundEconomic Burden of Treatment-Resistant Depression on the U.S. Health Care System
Sussman, M., O’sullivan, A. K., Shah, A., Olfson, M., & Menzin, J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.7.823 · Cited by 65
Medicare patient experience with vagus nerve stimulation for treatment-resistant depression
Feldman, R. L., Dunner, D. L., Muller, J. S., & Stone, D. A. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.724745 · Cited by 61
McIntyre, R. S., Millson, B., & Power, G. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.045 · Cited by 60
Cepeda, M. S., Reps, J., Fife, D., Blacketer, C., Stang, P., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22705 · Cited by 50
Olfson, M., Amos, T. B., Benson, C., McRae, J., & Marcus, S. C. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.3.226 · Cited by 48
“Total health care costs, $ Total 17,997 (34,146) 10,325 (28,224) 6,749 (5,268-8,230) 5,923 (4,409-7,437) Mental health related 4,122 (8,657) 1,869 (6,643) 1,957 (1,586-2,327) 2,015 (1,607-2,423) Depression related 1,969 (4,203) 943 (3,314) 899 (725-1,072) 760 (595-925) Prescription pharmacy costs, $ Total 4,986 (9,529…”
Hollinghurst, S., Carroll, F. E., Abel, A., Campbell, J., Garland, A., Jerrom, B., Kessler, D., Kuyken, W., Morrison, J., Ridgway, N., et al. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.125286 · Cited by 36
Adu, M. K., Shalaby, R., Chue, P., & Agyapong, V. I. O. (2022) · Behavioral Sciences · doi:10.3390/bs12060195 · Cited by 31
“As a result of the potential, high, direct and indirect medical costs, which further increase the severity of TRD, clinicians are in search of empirical evidence to guide in the choice of the most effective treatment for TRD [17].”
BackgroundTreatment resistant depression in women with peripartum depression
Cepeda, M. S., Kern, D. M., & Nicholson, S. (2019) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-019-2462-9 · Cited by 31
Costa, T., Menzat, B., Engelthaler, T., Fell, B., Franarin, T., Roque, G., Wei, Y., Zhang, X., & McAllister-Williams, R. H. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221090628 · Cited by 22
“In addition, more treatment failures, and thus a greater degree of TRD, are associated with higher health care costs (Johnston et al., 2019; Russell et al., 2004).”
Background(2013) · PubMed · Cited by 20
Assessing potential of psilocybin for depressive disorders
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273493 · Cited by 11
Metadata
- Authors
- Russell, J. M., Hawkins, K., Ozminkowski, R. J., Orsini, L., Crown, W. H., Kennedy, S., Finkelstein, S., Berndt, E., & Rush, A. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-03-15
- Volume
- 65
- Issue
- 3
- Pages
- 341-347
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2027061717
- Cited by
- 117
- References
- 0
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.